Skip to main content
SpringerLink
Log in

New Agents, New Trials, New Solutions

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Dramatic advances in biological understanding, coupled with improved knowledge about appropriate clinical trial design and transformation of the healthcare system into a business paradigm, have created a dynamic situation for evaluating new therapies for patients with acute ischemic syndromes. Multiple avenues for alteration of the basic components of acute ischemia are possible, ranging from manipulation of the coagulation system to stabilization of the vulnerable atherosclerotic plaque. The trials required to demonstrate a role for such therapies must involve large numbers of patients and must measure clinical outcomes rather than pathophysiological surrogates. Given the increasing restriction of the rate of growth of funding for medical care, it is more important than ever that new therapies demonstrate cost effectiveness and practical feasibility. While current clinical trials focus on thrombolytic agents, antithrombin agents, and platelet glycoprotein IIb/IIIa inhibitors, future trials will address multiple other biological targets. The clinical community bears the responsibility of developing methods to rapidly assess these potential advances.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. GUSTO IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The global use of strategies to open occluded coronary arteries. N Engl J Med 1996;335:775–782.

    Article  Google Scholar 

  2. Antman EM, for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: Safety report from the Thrombolysis and thrombin inhibition In Myocardial Infarction (TIMI) 9A trial. Circulation 1994;90:1624–1630.

    PubMed  CAS  Google Scholar 

  3. FRISC Study Group. Low-molecular-weight heparin during instability in coronary artery disease, fragmin during instability in coronary artery disease. Lancet 1996;347:561–568.

    Google Scholar 

  4. Turpie AGG, Ruddy TD, Sussex BA, Nawaz S, Gill JB, Latour Y, Leclerc J, Prewitt RM, Sinha SN, and the EPIC Investigators. Low molecular weight heparin (dalteparin) in unstable coronary artery disease FRIC (abstr). Can J Cardiol 1995;11 (Suppl. E):110E.

    Google Scholar 

  5. Kol A, Sperti G, Shani J, Schulhoff N, van de Greef W, Landini MP, La Placa M, Maseri A, Crea F. Cytomegalovirus replication is not a cause of instability in unstable angina. Circulation 1995;91:1910–1913.

    PubMed  CAS  Google Scholar 

  6. Mendall MA, Goggin PM, Molineaux N, Levy J, Toosy T, Strachan D, Camm AJ, Northfield TC. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J 1994;71:437–439.

    PubMed  CAS  Google Scholar 

  7. Kuo CC, Shor A, Campbell LA, Fukushi H, Patton DL, Grayston JT. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis 1993;167:841–849.

    PubMed  CAS  Google Scholar 

  8. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995;91:2844–2850.

    PubMed  CAS  Google Scholar 

  9. Lee RT, Schoen FJ, Loree HM, Lark MW, Libby P. Circumferential stress and matrix metalloproteinase 1 in human coronary atherosclerosis. Implications for plaque rupture. Arterioscler Thromb Vasc Biol 1996;16:1070–1073.

    PubMed  CAS  Google Scholar 

  10. Kaartinen M, Pentilla A, Kovanen PT. Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation 1994;90:1669–1678.

    PubMed  CAS  Google Scholar 

  11. The Epic Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330: 956–961.

    Article  Google Scholar 

  12. Ferguson JJ. EPILOG and CAPTURE trials halted because of positive interim results. Circulation 1996;93:637.

    PubMed  Google Scholar 

  13. The IMPACT II Investigators. Randomized placebo-enrolled trial of effect of epti~batide complications of percutaneous coronary intervention. Lancet 1996, submitted.

  14. Antman EM, Lau J, Kupernick B, Mosteller R, Chalmers TC. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts: Treatments for myocardial infarction. JAMA 1992;268: 240–248.

    Article  PubMed  CAS  Google Scholar 

  15. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. JAMA 1988;260:2259–2263.

    Article  PubMed  CAS  Google Scholar 

  16. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4. A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 48,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669–685.

    Article  Google Scholar 

  17. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitate singly and together on 6–week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115–1121.

    Google Scholar 

  18. Fleming TR, DeMets DL. Surrogate end points in clinical trials: Are we being misled? Ann Intern Med 1996;125: 605–613.

    PubMed  CAS  Google Scholar 

  19. Fleming TR, Prentice RL, Pepe MS, Glidden D. Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research. Stat Med 1994;13:955–968.

    PubMed  CAS  Google Scholar 

  20. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, _ecainide, or placebo. N Engl J Med 1991;324:781–788.

    Article  PubMed  CAS  Google Scholar 

  21. Connolly SJ, Cairns JA. Prevalence and predictors of ventricular premature complexes in survivors of acute myocardial infarction. CAMIAT Pilot Study Group. Canadian Amio-New Agents, New Trials, New Solutions S157 darone Myocardial Infarction Arrhythmia Trial. Am J Cardiol 1992;69:408–411.

    Article  PubMed  CAS  Google Scholar 

  22. Connolly SJ, Cairns JA, Gent M, Roberts RS, CAMIAT Investigators. Which patients surviving acute myocardial infarction are most likely to bene~t from amiodarone (abstr). Circulation 1996;94(Suppl):I246.

    Google Scholar 

  23. Akiyama T, Pawitan Y, Greenberg H, Kuo CS, Reynolds-Haertle RA. Increased risk of death and cardiac arrest from encainide and _ecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial: CAST investigators. Am J Cardiol 1991;68: 1551–1555.

    Article  PubMed  CAS  Google Scholar 

  24. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, DeMets DL, for the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468–1475.

    Article  PubMed  CAS  Google Scholar 

  25. Packer M, Rouleau J, Swedberg K, Pitt B, Fisher L, Klepper M, and the PROFILE Investigators & Coordinators. Effect of flosequinan on survival in chronic heart failure: Preliminary results of the PROFILE study (abstr). Circulation 1993;88 Suppl:I301.

    Google Scholar 

  26. Goldman L, Hashimoto B, Cook EF, Loscalzo A. Comparative reproducibility and validity of systems for assessing cardiovascular functional class: Advantages of a new specific activity scale. Circulation 1981;64:1227–1134.

    PubMed  CAS  Google Scholar 

  27. Hlatky MA, Boineau RE, Higginbotham MB, Lee KL, Mark DB, Califf RM, Cobb FR, Pryor DB. A brief self-administered questionnaire to determine functional capacity, the Duke activity status index. Am J Cardiol 1989;651–654.

  28. Simes RJ. Publication bias: The case for an international registry of clinical trials. J Clin Oncol 1986;4:1529–1541.

    PubMed  CAS  Google Scholar 

  29. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet 1991;337:867–872.

    Article  PubMed  CAS  Google Scholar 

  30. Topol EJ, Califf RM, Van de Werf F, Simoons ML, Hampton JR, Lee KL, White HD, Simes RJ, Armstrong PW, for the VIGOUR Group. Perspectives onlarge scale cardiovascular clinical trials for thenewmillenium.Circulation 1997;97:1072–1082.

    Google Scholar 

  31. Topol EJ, Armstrong P, Van de Werf F, Kleiman N, Lee K, Morris D, Simoons M, Barbash G, White H, Califf RM, on behalf of the Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded Coronary Arteries (GUSTO) Steering Committee. Confronting the issues of patient safety and investigator con_ict of interest in an international clinical trial of myocardial infarction. J Am Coll Cardiol 1992;19:1123–1128.

    PubMed  CAS  Google Scholar 

  32. Armstrong PW, Furberg CD. Clinical trial data and safety monitoring boards: The search for a constitution. Circulation 1995;91:901–904.

    PubMed  CAS  Google Scholar 

  33. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence ofmyocardial infarction and death in patientswith unstable angina. JAMA 1996;276:811–815.

    Article  PubMed  CAS  Google Scholar 

  34. Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992;327:141–145.

    Article  PubMed  CAS  Google Scholar 

  35. Granger CB, Miller JM, Bovill EG, Gruber A, Tracy RP, Krucoff MW, Green C, Berrios E, Harrington RA, Ohman EM, Califf RM. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 1995;91: 1929–1935.

    PubMed  CAS  Google Scholar 

  36. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992;79:1–17.

    PubMed  CAS  Google Scholar 

  37. Hsia J, Kleiman N, Aguirre F, Chaitman BR, Roberts R, Ross AM, for the HART Investigators. Heparin-induced prolongation of partial thromboplastin time after thrombolysis: Relation to coronary artery patency. HART investigators. J Am Coll Cardiol 1992;20:31–35.

    PubMed  CAS  Google Scholar 

  38. de Bono DP, Simoons ML, Tijssen J, Arnold AE, Betriu A, Burgersdijk C, Lopez Bescos L, Mueller E, Pfisterer M, Van de Werf F. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: Results of a randomised double blind European Cooperative Study Group trial. Br Heart J 1992;67:122–128.

    PubMed  CAS  Google Scholar 

  39. Narins CR, Hillegass WB Jr., Nelson CL, Tcheng J, Harrington RA, Phillips HR, Stack RS, Califf RM. Relation between activated clotting time during angioplasty and abrupt closure. Circulation 1996;93:667–671.

    PubMed  CAS  Google Scholar 

  40. Granger CB, Hirsh J, Califf RM, Col J, White HD, Betriu A, Woodlief LH, Lee KL, Bovill EG, Simes J, Topol EJ, for the GUSTO-I1 Investigators. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: Results from the GUSTO-I trial. Circulation 1996;93:870–878.

    PubMed  CAS  Google Scholar 

  41. Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS, Becker RC, Kleiman NS, Haugland M, Anderson JL, Sharaf BL, Edwards SJ, Rogers WJ, Williams DO, Braunwald E, for the TIMI 5 Investigators. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: Results of the Thrombolysis In Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol 1994;23:993–1003.

    PubMed  CAS  Google Scholar 

  42. Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med 1995;155:601–607.

    Article  PubMed  CAS  Google Scholar 

  43. Clagett GP, Anderson FA, Heit J, Levine MN, Wheeler HB. Prevention of venous thromboembolism. Chest 1995;108(4 Suppl.):312S–334S.

    PubMed  CAS  Google Scholar 

  44. Cohen M, Demers C, Gurfinkel E, Fromell G, Langer A, Turpie AGG, ESSENCE Group. Primary end point analysis from the ESSENCE trial: Enoxaparin vs. unfractionated heparin in unstable angina and non-Q wave infarction. Circulation 1996;94(Suppl I):I554.

    Google Scholar 

  45. Neuhaus KL, v. Essen R, Tebbe U, Jessel A, Heinrichs H, Maurer W, Doring W, Harmjanz D, Kotter V, Kalhammer E, Simon H, Horacek T. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study: A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte (ALKK). Circulation 1994;90:1638–1642.

    PubMed  CAS  Google Scholar 

  46. Kleiman NS, Ohman EM, Califf RM, George BS, Kereiakes D, Aguirre FV, Weisman H, Schaible T, Topol EJ. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 fab following thrombolytic therapy: Results of the TAMI 8 pilot study. J Am Coll Cardiol 1993;22:381–389.

    PubMed  CAS  Google Scholar 

  47. Ferguson JJ. Meeting highlights: American College of Cardiology 45th Annual Scientific Session, Orlando, Florida, March 24 to 27, 1996. Circulation 1996;94:1–5.

    PubMed  CAS  Google Scholar 

  48. Theroux P, Kouz S, Roy L, Knudtson ML, Diodati JG, Marquis JF, Nasmith J, Fung AY, Boudreault JR, Delage F, Dupuis R, Kells C, Bokslag M, Steiner B, Rapold HJ. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina – the Canadian lami~ban study. Circulation 1996;94:899–905.

    PubMed  CAS  Google Scholar 

  49. Schulman SP, Goldschmidt-Clermont PJ, Navetta FI, Chandra NC, Guerci AD, Califf RM, Ferguson JJ, Willerson JT, Wolfe CL, Bahr R, Yakubov SJ, Nyggard TW, Mason SJ, Brashears L, Charo I, du Mee C, Kitt MM, Gerstenblith GG. Integrelin in unstable angina: A double-blind randomized trial (abstr). Circulation 1993;88(Suppl I):I608.

    Google Scholar 

  50. Ohman EM, Kleiman NS, Gacioch G, Talley D, Navetta FI, Worley S, Anderson RD, Cohen J, Kereiakes DJ, Sigmon KN, Krucoff MW, Califf RM, Topol EJ, for the IMPACTAMI Investigators. Combined accelerated tissue plasminogen activator and platelet glycoprotein IIb/IIIa integrin blockade with Integrilin (TM) in acute myocardial infarction: Results from a randomized, placebo-controlled, dose-ranging trial. Circulation, 1997;95:846–854.

    PubMed  CAS  Google Scholar 

  51. Moliterno DJ, Harrington RA, Krucoff MW, Armstrong PW, Van de Werf F, Kristinsson A, Hui W, Paraschos A, Bhapkar M, Rames A, Topol EJ, PARADIGM Investigators. More complete and stable reperfusion with platelet IIb/IIIa antagonism plus thrombolysis for AMI: The PARADIGM trial (abstr). Circulation 1996;94(Suppl.):I553.

    Google Scholar 

  52. Harrington RA, Moliteno DJ, van der Werf F, Keech A, Kleiman NS, Bhapkar M, Romeo A, Peek M, Topol EJ, Califf RM, Armstrong PN for the paragon investigators. Delaying and preventing ischemic events in patients with acute coronary syndromes using the platelet glycoprotein IIb/IIIa inhibitor Lamifiban. J Am Coll Cardiol 1997;29(Suppl):409A (abstract)

    Google Scholar 

  53. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 1994;90:775–778.

    PubMed  CAS  Google Scholar 

  54. Muller JE, Abela GS, Nesto RW, et al. Triggers, acute risk factors and vulnerable plaques: The lexicon of a new frontier. J Am Coll Cardiol 1994;23:809–813.

    Article  PubMed  CAS  Google Scholar 

  55. Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O'Keefe J, Overlie P, Donohue B, Chelliah N, Timmis GC, Vlietstra RE, Strzelecki M, Puchrowicz-Ochocki S, O'Neill WW, for the Primary Angioplasty In Myocardial Infarction Study Group. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1993;328:673–679.

    Article  PubMed  CAS  Google Scholar 

  56. Zijlstra F, de Boer MJ, Hoorntje JC, Reiffers S, Reiber JH, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993;328:680–684.

    Article  PubMed  CAS  Google Scholar 

  57. Vassanelli C, Ellis SG, Phillips HR, Betriu A, Van de Werf F, Stebbins A. Primary percutaneous transluminal coronary angioplasty for acute myocardial infarction (abstr). Circulation 1996;94(Suppl.):I329.

    Google Scholar 

  58. TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis In Myocardial Infarction (TIMI) phase II trial. N Engl J Med 1989;320:618–627.

    Article  Google Scholar 

  59. Bates ER, Califf RM, Stack RS, Aronson L, George BS, Candela RJ, Kereiakes DJ, Abbottsmith CW, Anderson L, Pitt B, O'Neill WW, Topol EJ, The Thrombolysis and Angioplasty in Myocardial Infarction Study Group. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI-1) trial: In_uence of infarct location on arterial patency, left ventricular function and mortality. J Am Coll Cardiol 1989;13:12–18.

    PubMed  CAS  Google Scholar 

  60. Arnold AE, Simoons ML, Detry JM, von Essen R, Van de Werf F, Deckers JW, Lubsen J, Verstraete M. Prediction of mortality following hospital discharge after thrombolysis for acute myocardial infarction: Is there a need for coronary angiography? European cooperative study group. Eur Heart J 1993;14:306–315.

    PubMed  CAS  Google Scholar 

  61. Aguirre FV, Topol EJ, Ferguson JJ, Anderson K, Blankenship JC, Heuser RR, Sigmon K, Taylor M, Gottlieb R, Hanovich G, Rosenberg M, Donohue TJ, Weisman HF, Califf RM, for the EPIC Investigators. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation 1995;91:2882–2890.

    PubMed  CAS  Google Scholar 

  62. OASIS Investigators. Randomized controlled trial comparing hirudin with heparin and warfarin with control for unstable angina and non Q wave MI. Can J Cardiol 1995;11(Suppl. E):110E.

    Google Scholar 

  63. Theroux P, Perez-Villa F, Waters D, Lesperance J, Shabani F, Bonan R. Randomized double-blind comparison of two doses of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation 1995;91:2132–2139.

    PubMed  CAS  Google Scholar 

  64. Metz BK, Granger CB, White HD, Simes J, Topol EJ. Streptokinase and hirudin reduces death and reinfarction in acute myocardial infarction compared with streptokinase and heparin: Results from GUSTO IIb (abstr). Circulation 1996;94(Suppl. J):I430.

    Google Scholar 

  65. Lazzarino G, Nuutinen ME, Tavazzi B, Cerroni L, Di Pierro D, Giardina B. Preserving effect of fructose-1,6–diphosphate on high energy phosphate compounds during anoxia and reperfusion in isolated Langendorff-perfused rat hearts. J Mol Cell Cardiol 1991;23:13–23.

    Article  PubMed  CAS  Google Scholar 

  66. Markov AK, Oglethorpe NC, Blake TM, Lehan PH, Hellems HK. Hemodynamic, electrocardiographic, and metabolic effects of fructose diphosphate on acute myocardial ischemia. Am Heart J 1980;100:639–646.

    Article  PubMed  CAS  Google Scholar 

  67. Garcia-Dorado D, Theroux P, Duran JM, Solares J, Alonso J, Sanx E, Monoz R, Elizaga J, Botas J, Fernandez-Aviles F, Soriano J, Esteban E. Selective inhibition of the contractile apparatus. A new approach to modi~cation of infarct size, infarct composition, and infarct geometry during coronary occlusion and reperfusion. Circulation 1992;84:1160–1174.

    Google Scholar 

  68. Wall TC, Califf RM, Blankenship J, Talley JD, Tannenbaum M, Schwaiger M, Gacioch G, Cohen MD, Sanz M, Leimberger JD, Topol EJ, the TAMI 9 Research Group. Intravenous fluosol in the treatment of acute myocardial infarction: Results of the Thrombolysis and Angioplasty in Myocardial Infarction 9 Trial. Circulation 1994;90:114–120.

    PubMed  CAS  Google Scholar 

  69. Williams RE, Zweier JL, Flaherty JT. Treatment with deferoxamine during ischemia improves functional and metabolic recovery and reduces reperfusion-induced oxygen radical generation in rabbit hearts. Circulation 1991;83:1006–1014.

    PubMed  CAS  Google Scholar 

  70. Okeefe JH, Grines CL, DeWood MA, Schaer GL, Browne K, Magorien RD, Kalbfleisch JM, Fletcher WO, Bateman TM, Gibbons RJ. Poloxamer-188 as an adjunct to primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. AM J Cardiol 1996;78:747–750.

    Article  CAS  Google Scholar 

  71. Schaer GL, Spaccavento LJ, Browne KF, Krueger KA, Krichbaum D, Phelan JM, Fletcher WO, Grines CL, Edwards S, Jolly MK, Gibbons RJ. Beneficial effects of rheothrx injection in patients receiving thrombolytic therapy for acute myocardial infarction – results of a randomized, doubleblind, placebo-controlled trial. Circulation 1996;94:298–307.

    PubMed  CAS  Google Scholar 

  72. Pitarys CJ, Virmani R, Vildibill HD, Jackson EK, Forman MB. Reduction of myocardial reperfusion injury by intravenous adenosine administered during the early reperfusion period. Circulation 1991;83:237–247.

    PubMed  Google Scholar 

  73. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: An overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335–371.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, Department of Medicine and the Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA

    Robert M. Califf & Robert A. Harrington

Authors
  1. Robert M. Califf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert A. Harrington
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Califf, R.M., Harrington, R.A. New Agents, New Trials, New Solutions. J Thromb Thrombolysis 5 (Suppl 2), S151–S159 (1998). https://doi.org/10.1023/A:1008838318526

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1008838318526

Keywords

Search

Navigation